HomeCompareYMAB vs HDV

YMAB vs HDV: Dividend Comparison 2026

YMAB yields 23.23% · HDV yields 2.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 YMAB wins by $64.5K in total portfolio value
10 years
YMAB
YMAB
● Live price
23.23%
Share price
$8.61
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$88.8K
Annual income
$9,382.37
Full YMAB calculator →
HDV
iShares Core High Dividend ETF
● Live price
2.92%
Share price
$135.39
Annual div
$3.96
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.3K
Annual income
$352.73
Full HDV calculator →

Portfolio growth — YMAB vs HDV

📍 YMAB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodYMABHDV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, YMAB + HDV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
YMAB pays
HDV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

YMAB
Annual income on $10K today (after 15% tax)
$1,974.45/yr
After 10yr DRIP, annual income (after tax)
$7,975.01/yr
HDV
Annual income on $10K today (after 15% tax)
$248.52/yr
After 10yr DRIP, annual income (after tax)
$299.82/yr
At 15% tax rate, YMAB beats the other by $7,675.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of YMAB + HDV for your $10,000?

YMAB: 50%HDV: 50%
100% HDV50/50100% YMAB
Portfolio after 10yr
$56.6K
Annual income
$4,867.54/yr
Blended yield
8.60%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YMAB right now

YMAB
Analyst Ratings
8
Buy
6
Hold
2
Sell
Consensus: Buy
Price Target
$12.71
+47.6% upside vs current
Range: $8.60 — $24.00
Altman Z
2.7
Piotroski
3/9
HDV
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

YMAB buys
0
HDV buys
0
No recent congressional trades found for YMAB or HDV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricYMABHDV
Forward yield23.23%2.92%
Annual dividend / share$2.00$3.96
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$88.8K$24.3K
Annual income after 10y$9,382.37$352.73
Total dividends collected$54.4K$3.2K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: YMAB vs HDV ($10,000, DRIP)

YearYMAB PortfolioYMAB Income/yrHDV PortfolioHDV Income/yrGap
1← crossover$13,023$2,322.88$11,002$292.38+$2.0KYMAB
2$16,762$2,827.16$12,084$300.36+$4.7KYMAB
3$21,336$3,400.76$13,250$308.02+$8.1KYMAB
4$26,875$4,045.60$14,506$315.35+$12.4KYMAB
5$33,519$4,762.52$15,858$322.35+$17.7KYMAB
6$41,416$5,551.28$17,313$329.04+$24.1KYMAB
7$50,726$6,410.53$18,878$335.42+$31.8KYMAB
8$61,614$7,337.86$20,560$341.49+$41.1KYMAB
9$74,257$8,329.89$22,367$347.25+$51.9KYMAB
10$88,838$9,382.37$24,307$352.73+$64.5KYMAB

YMAB vs HDV: Complete Analysis 2026

YMABStock

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Full YMAB Calculator →

HDVETF

The iShares Core High Dividend ETF seeks to track the investment results of an index composed of relatively high dividend paying U.S. equities.

Full HDV Calculator →
📬

Get this YMAB vs HDV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

YMAB vs SCHDYMAB vs JEPIYMAB vs OYMAB vs KOYMAB vs MAINYMAB vs VYMYMAB vs DVYYMAB vs SPHD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.